Punit Dhillon has been given A+ recommendation by these 8 reknown MDs/PhDs that provide their expertise plus reknown credentials to OncoSec and Punit Dhillon
Dr. Heller has over 25 years of experience in evaluating effects of electric pulses on biological systems. He is recognized as a pioneer on the use of electrotransfer for drug and gene delivery.
His research group has developed new protocols or devices that are being tested for potential therapies for cancer, wound healing and vascular diseases (peripheral or coronary ischemia) as well as vaccine and immunotherapy protocols. His work in this gene therapy approach was translated into the clinic and represents the first-in-human study utilizing in vivo gene electrotransfer of a plasmid. Richard Heller is currently Director of the Frank Reidy Research Center for Bioelectrics (CBE) and Professor in the School of Medical Diagnostics and Translational Sciences in the College of Health Sciences at Old Dominion University (ODU).
(2)Dr. Iacon Mathiesen
Dr. Mathiesen has a PhD from University of Oslo, Norway. He was a co-founder of Inovio AS, Norway and inventor on numerous electroporation related patents covering devices and methods for gene based immune therapy. After Inovio AS was acquired by Genetronics Biomedical in 2005 (now Inovio Pharmaceuticals), IM was director of gene delivery at Inovio in San Diego. Iacob has more than 10 years’ experience with IP, electroporation devices and methods and worked closely with University of Southampton to initiate the first human clinical trial using electroporation do delivery a gene based vaccine. Iacob is currently CEO of Otivio AS in Norway, a new startup developing methods and devices for wound healing and temperature management.
(3)Dr. Christian Ottensmeier
Dr. Ottensmeier leads the Experimental Cancer Medicine Centre in Southampton and his core academic interest is the early translation of immunotherapeutic strategies into the clinic. His clinical interests are thoracic malignancies and melanoma, and he has co-developed a number of national NCRI studies in lung cancer. He manages a broad and active portfolio of clinical trials in both lung cancer and melanoma.
He has served on a number of industry advisory boards and DSMBs for industry led studies and is also a member of the Clinical Development partnership between Cancer Research UK and Astra Zeneca. He is a member of a number of national peer reviewed funding committees.
Melanoma Advisory Board
(4)Dr. Axel Hauschild
Axel Hauschild, MD, PhD, is professor and head of the “Interdisciplinary Skin Cancer Center” at the Department of Dermatology, University Hospital Schleswig-Holstein in Kiel, Germany.
He is board certified in general dermatology and dermato-oncology. From 2002 to 2010 he was the chairman of the Dermatologic Cooperative Oncology Group (DeCOG) in Germany. Dr. Hauschild is a board member of the European Association of Dermato-Oncology (EADO) and the co-chairman of the Global Melanoma Task Force (GMTF).
(5)Dr. Sanjiv S. Agarwaia
Dr. Agarwala is Chief of Medical Oncology & Hematology and Director of the Melanoma and Immunology Program at St. Luke’s Cancer Center, Bethlehem, PA. He is Professor of Medicine at Temple University School of Medicine, Philadelphia, PA. He is nationally and internationally recognized as an expert in the research and treatment of melanoma.
He has been Principal Investigator for several clinical trials involving immunotherapy and targeted therapy for melanoma and other malignancies. He has over 100 publications and book chapters written on melanoma and other research areas. He is board certified in Oncology, Hematology and Internal Medicine and is an active member of several professional and scientific societies including the American Association for Cancer Research, the American Society of Clinical Oncology and the European Society of Medical Oncology and the Society for Melanoma Research.
(6)Dr. Vernon K. Sondak
Vernon Sondak is Chair of the Department of Cutaneous Oncology and Director of Surgical Education at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. He is also a Professor in the Departments of Oncologic Sciences and Surgery at the University of South Florida Morsani College of Medicine.
Dr. Sondak has been a leader in studies of surgical treatment of melanoma and other cutaneous malignancies, particularly in the application of sentinel lymph node biopsy to the staging of melanoma and Merkel cell carcinoma. He is actively involved in ongoing analyses to determine which patients with thin melanoma are most likely to benefit from sentinel node biopsy, as well as which patients with sentinel node metastases are most likely to have further metastases identified in other regional lymph nodes.
(7)Dr. Kim A. Margolin
Kim A. Margolin, MD, is Professor of Medicine at the University of Washington in Seattle and a member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center. Dr. Margolin served as chair of the Cancer Education Committee for ASCO in 2010 and has previously served on the Board of Directors of the Society for Immunotherapy of Cancer, the Medical Oncology Boards subcommittee of the ABIM (2002-2008), and the Oncologic Drugs Advisory Committee to the FDA (1994-2000).
Dr. Margolin earned her BS at the University of California at Los Angeles (UCLA) and completed her medical education at Stanford University, housestaff training at Yale and fellowships at UC San Diego and City of Hope in medical oncology and bone marrow transplantation.
(8)Dr. Adil Daud
Dr. Adil Daud is is a professor of medicine at UCSF and a nationally recognized expert in early phase drug development in skin cancer and solid tumors. He earned a medical degree at the Government Medical College in Nagpur, India. He completed an internship and residency in internal medicine at Indiana University Medical Center, followed by a fellowship in hematology-oncology at Memorial Sloan-Kettering Cancer Center.
Prior to joining UCSF Medical Center, he was Associate Professor and Director of the Affiliate Network at the Moffitt Cancer Center in Tampa, Fla. for seven years. Daud has won numerous awards, including the American Society for Clinical Oncology’s Young Investigator award and Castle Connolly’s Best Doctors in America award.
News 
Market Data 
Discover 
AI
